Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.16399
Abstract: The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected… read more here.
Keywords: cne2r cd166; response; cd166 cells; cd166 ... See more keywords